Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Paz J. Vellanki"'
Autor:
Harpreet Singh, Richard Pazdur, Paz J Vellanki, Soma Ghosh, Anand Pathak, Michael J Fusco, Erik W Bloomquist, Shenghui Tang, Reena Philip, Julia A Beaver
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 2 (2023)
In the era of precision oncology, use of circulating tumor DNA (ctDNA) is emerging as a minimally invasive approach for the diagnosis and management of patients with cancer and as an enrichment tool in clinical trials. In recent years, the US Food an
Externí odkaz:
https://doaj.org/article/a1499317868244fbb8819e439ccec5b0
Autor:
Harpreet Singh, Julia A. Beaver, Richard Pazdur, Dianne Spillman, Nataliya Fesenko, Ulrich-Peter Rohr, Arūnas Girčys, Qiuyi Choo, Aleksandr Gamarian, Elitza Palazov, Jeanne Fourie Zirkelbach, Jiang Liu, Yangbing Li, Huiming Xia, Yuan Li Shen, Pallavi S. Mishra-Kalyani, Xiaoxue Li, Nicole Drezner, Paz J. Vellanki, Abigail L. Koch
Lung Cancer Staging per AJCC 7th and 8th Editions
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02ea844594f3376770c9d06602668779
https://doi.org/10.1158/1078-0432.22484015
https://doi.org/10.1158/1078-0432.22484015
Autor:
Elitza Palazov, Yangbing Li, Harpreet Singh, Jeanne Fourie Zirkelbach, Julia A. Beaver, Dianne Spillman, Arūnas Girčys, Jiang Liu, Aleksandr Gamarian, Huiming Xia, Qiuyi Choo, Paz J. Vellanki, Pallavi S. Mishra-Kalyani, Nataliya Fesenko, Nicole Drezner, Ulrich-Peter Rohr, Richard Pazdur, Yuan Li Shen, Xiaoxue Li, Abigail L. Koch
Publikováno v:
Clinical Cancer Research. 27:6638-6643
On December 18, 2020, the FDA approved osimertinib as adjuvant therapy in patients with non–small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 (L858R) mutations, as detected by an FDA-approved test. The approval was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06a1241c1d69de4d61a6f32a05dbe4e2
https://doi.org/10.1158/1078-0432.ccr-21-1034
https://doi.org/10.1158/1078-0432.ccr-21-1034
Autor:
Kristen E. Schratz, Diane A. Flasch, Christine C. Atik, Zoe L. Cosner, Amanda L. Blackford, Wentao Yang, Dustin L. Gable, Paz J. Vellanki, Zhimin Xiang, Valeriya Gaysinskaya, Robert H. Vonderheide, Lisa M. Rooper, Jinghui Zhang, Mary Armanios
Publikováno v:
Cancer Cell. 41:807-817.e6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a4f159d757ffd190e38014f23dc4aef
https://doi.org/10.1016/j.ccell.2023.03.005
https://doi.org/10.1016/j.ccell.2023.03.005
Autor:
Paz J Vellanki, Soma Ghosh, Anand Pathak, Michael J Fusco, Erik W Bloomquist, Shenghui Tang, Harpreet Singh, Reena Philip, Richard Pazdur, Julia A Beaver
Publikováno v:
Journal for ImmunoTherapy of Cancer. 11:e005344
In the era of precision oncology, use of circulating tumor DNA (ctDNA) is emerging as a minimally invasive approach for the diagnosis and management of patients with cancer and as an enrichment tool in clinical trials. In recent years, the US Food an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed01d075efcae71a1cd43a3ce8f30eed
https://doi.org/10.1136/jitc-2022-005344
https://doi.org/10.1136/jitc-2022-005344
Autor:
Paz J. Vellanki, Hyunseok Kang, Lynn M. Schuchter, Mary Armanios, Ranee Mehra, Lisa M. Rooper, M. Malek Bawadkji, Emily A. DeBoy
Publikováno v:
JCO Precis Oncol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c80ca8dab1f2c6e573148398413b38d
https://europepmc.org/articles/PMC8457871/
https://europepmc.org/articles/PMC8457871/
Autor:
Somak Chatterjee, Martha Donoghue, Pallavi S. Mishra-Kalyani, Harpreet Singh, Erin Larkins, Hong Zhao, Missiratch Biable, Youwei Bi, Julia A. Beaver, Jiang Liu, Hisham Qosa, Richard Pazdur, Erica C Nakajima, Paz J. Vellanki, Lauren Tesh Hotaki, Yuan Li Shen
Publikováno v:
Clin Cancer Res
On October 2, 2020, FDA approved nivolumab with ipilimumab as first-line treatment for adult patients with unresectable malignant pleural mesothelioma (MPM). The approval was based on results from Study CA209743 (CHECKMATE-743), an open-label trial o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::447f93a506322a4ba9d4950c4848a080
https://pubmed.ncbi.nlm.nih.gov/34462287
https://pubmed.ncbi.nlm.nih.gov/34462287
Autor:
Oladimeji Akinboro, Jonathon Joseph Vallejo, Erica C. Nakajima, Yi Ren, Pallavi Shruti Mishra-Kalyani, Erin A. Larkins, Paz J. Vellanki, Nicole Lauren Drezner, Luckson Noe Mathieu, Martha Boeri Donoghue, Shenghui Tang, Richard Pazdur, Julia A. Beaver, Harpreet Singh
Publikováno v:
Journal of Clinical Oncology. 40:9000-9000
9000 Background: FDA-approved 1L treatment options for patients with PD-L1-high advanced NSCLC (PD-L1 score ≥50%) include IO ± chemo (± anti-angiogenics) but it is unclear if chemo substantially improves efficacy outcomes when added to IO in this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::505bbfede2be65387d2ded14e6145864
https://doi.org/10.1200/jco.2022.40.16_suppl.9000
https://doi.org/10.1200/jco.2022.40.16_suppl.9000
Autor:
Yibo Wang, Yuan Xu, Adnan A. Jaigirdar, Sarah J. Golding, Dianne Spillman, Victoria Mansell, Flora Mulkey, R. Angelo de Claro, Kwadwo Korsah, Grant Howe, Julia A. Beaver, Richard Pazdur, Harpreet Singh, Jiang Liu, Qiuyi Choo, Paz J. Vellanki, Jian Wang, Hong Zhao, Lisa Rodriguez
Publikováno v:
Clin Cancer Res
On May 26, 2020, the U.S. Food and Drug Administration (FDA) approved nivolumab with ipilimumab and two cycles of platinum-doublet chemotherapy as first-line treatment for patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e483706027a6f61ca946907ee6b769c
https://pubmed.ncbi.nlm.nih.gov/33632925
https://pubmed.ncbi.nlm.nih.gov/33632925
Autor:
Harpreet Singh, Patricia Keegan, Paz J. Vellanki, Kunthel By, Erin A. Larkins, Shanthi Marur, Andrew T Girvin, Frank C. Cross, Marc R. Theoret, Pallavi S. Mishra-Kalyani, Richard Pazdur, Pradeep Bandaru, Somak Chatterjee
Publikováno v:
Journal of Clinical Oncology. 38:6509-6509
6509 Background: Recent evidence suggests that treatment with systemic antibiotics (Abx) disrupts the intestinal microbiome and may be associated with decreased survival for patients receiving treatment with ICIs for advanced cancers, including R/M H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca1340a83aa10ab26ea9cb6c1b6d93b7
https://doi.org/10.1200/jco.2020.38.15_suppl.6509
https://doi.org/10.1200/jco.2020.38.15_suppl.6509